Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise for Hard-to-Treat blood cancers

NCT ID NCT04278768

Terminated Disease control Sponsor: Curis, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an oral drug called emavusertib (CA-4948) in adults with acute myeloid leukemia (AML) or a high-risk bone marrow disorder (MDS) that have not responded to or returned after prior treatment. The goal is to find the safest and most effective dose and to see if the drug can shrink or control the cancer. Participants must have specific genetic mutations (FLT3, SF3B1, or U2AF1) and have had no more than two prior treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOGENOUS LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia hereditary sensory and autonomic neuropathy myelodysplastic syndrome Myelodysplastic Syndromes Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOGENOUS LEUKEMIA MYELODYSPLASTIC SYNDROME

Contacts and locations

Locations

  • APHP - Hopital Saint Louis

    Paris, 75475, France

  • APHP - Sorbonne Universite

    Paris, 75012, France

  • Albert Einstein Medical College

    The Bronx, New York, 10461, United States

  • Azienda Ospedaliera Santa Croce e Carle

    Cuneo, Italy

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Edith Wolfson Medical Center

    Holon, 5822012, Israel

  • Hadassah University MC

    Jerusalem, 9112001, Israel

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Hospital Universitaro del a Princesa

    Madrid, 28006, Spain

  • Hospital de la Santa Creu I Sant Pau (Neuvo Hospital)

    Barcelona, Spain

  • Instituto Romagnolo per lo Studio dei Tumori "Dino Amadori"

    Meldola, Italy

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Klinikum rechts der Isar der Technischen Universitat Munchen

    München, 81675, Germany

  • MD Anderson Cancer Center Madrid

    Madrid, Spain

  • Marien Hospital Dusseldorf; Klinik fur Onkologie und Hamatologie, Palliativmedizin

    Düsseldorf, 40479, Germany

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Northwestern Memorial Hospital

    Chicago, Illinois, 60611, United States

  • Novant Health Hematology - Forsyth

    Winston-Salem, North Carolina, 27103, United States

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists

    Omaha, Nebraska, 68130, United States

  • Service d'hématologie clinique CHU de Nice

    Nice, 6200, France

  • Soroka University MC

    Beersheba, 84100, Israel

  • The Ohio State University Wexner Medical Center - James Cancer Hospital

    Columbus, Ohio, 43210, United States

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Universitatsklinikum Leipzig; Medizinische Klinik und Poliklinik I

    Leipzig, 04103, Germany

  • Universitatsklinikum Munster

    Münster, 48149, Germany

  • University Hospital in Krakow

    Krakow, 31 501, Poland

  • University of Chicago Medical Center

    Chicago, Illinois, 60637, United States

  • University of Rochester Medical Center

    Rochester, New York, 14642, United States

  • Universitätsklinikum Hamburg-Eppendorf (UKE)

    Hamburg, 20246, Germany

  • Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz

    Gdansk, 80-214, Poland

  • Vseobecna Fakultni nemocnice v Praze

    Prague, 12 808, Czechia

  • Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.